Macular atrophy at 5 years after photodynamic therapy for polypoidal choroidal vasculopathy

Purpose To investigate predictors for macular atrophy (MA) involving the fovea after photodynamic therapy (PDT) followed by pro re nata (PRN) treatment for polypoidal choroidal vasculopathy (PCV). Methods This prospective observational study analysed treatment-naive eyes with symptomatic PCV without MA at baseline which were followed up for 5 years. All eyes were initially treated with PDT, followed by a PRN regimen of anti-vascular endothelial growth factor (VEGF) therapy and/or PDT. We assigned eyes with and eyes without development of MA involving the fovea 5 years after the initial treatment into MA and non-MA groups, respectively. Baseline parameters and the number of treatments were compared between the two groups. Results Seventy-two eyes of 69 consecutive patients were included, and 29 eyes of 29 patients were analysed. Twelve (41%) and 17 (59%) eyes were assigned into the MA and non-MA groups, respectively. There were significant differences in subfoveal choroidal thickness (226.2 +/- 47.8 mu m vs. 278.8 +/- 68.1 mu m, P = 0.03) and number of anti-VEGF injections (13.7 +/- 9.6 vs. 5.4 +/- 5.6, P = 0.007) between the MA and non-MA groups, but not in the number of PDT sessions (P = 0.71). Best-corrected visual acuity at 5 years in the MA group was lower than in the non-MA group (P = 0.048). Conclusion Our long-term observation suggests that a thin subfoveal choroid at baseline and many followed anti-VEGF injections in a PRN regimen increase the risk for development of MA involving the fovea 5 years after PDT.

Automated summary

This study found that a thin subfoveal choroid at baseline and multiple anti-VEGF injections in a PRN regimen increase the risk of developing macular atrophy (MA) involving the fovea after photodynamic therapy (PDT) and PRN treatment.